Loss of the cell adhesion protein E-cadherin increases the invasive capability of ovarian cancer cells. We have previously shown that epidermal growth factor (EGF) downregulates E-cadherin and induces ovarian cancer cell invasion through the H 2 O 2 /p38 MAPK-mediated upregulation of the E-cadherin transcriptional repressor Snail. However, the molecular mechanisms underlying the EGF-induced downregulation of E-cadherin are not fully understood. In the current study, we demonstrated that treatment of two ovarian cancer cell lines, SKOV3 and OVCAR5, with EGF induced the expression of the transcription factor Egr-1, and this induction was abolished by small interfering RNA (siRNA)-mediated depletion of the EGF receptor. EGF-induced Egr-1 expression required the activation of the ERK1/2 and PI3K/Akt signaling pathways and was unrelated to EGF-induced H 2 O 2 production and activation of the p38 MAPK pathway. Moreover, depletion of Egr-1 with siRNA abolished the EGF-induced downregulation of E-cadherin and increased cell invasion. Interestingly, siRNA depletion of Egr-1 attenuated the EGF-induced expression of Slug, but not that of Snail. Moreover, chromatin immunoprecipitation (ChIP) analysis showed that Slug is a target gene of Egr-1. These results provide evidence that Egr-1 is a mediator that is involved in the EGF-induced downregulation of E-cadherin and increased cell invasion. Our results also demonstrate that EGF activates two independent signaling pathways, which are the H 2 O 2 /p38 MAPK-mediated upregulation of Snail expression and the Egr-1-mediated upregulation of Slug expression. These two signaling pathways contribute to the EGF-induced downregulation of E-cadherin, which subsequently increases the invasive capability of ovarian cancer cells.
INTRODUCTION
E-cadherin is a 120-kDa transmembrane glycoprotein that is localized to the surface of epithelial cells in regions of cell-cell contact, which are known as adherens junctions. E-cadherin is involved in calcium-dependent cell-cell adhesion, which maintains cell polarity and normal epithelial structure. 1 The cytoplasmic portion of E-cadherin is bound to the actin cytoskeleton via catenin proteins to mediate mechanical stability. 2 The loss of E-cadherin is the hallmark of epithelial-mesenchymal transition, which has been shown to have an important role in tumorigenesis. 3 Many studies have shown that the components of the extracellular matrix, growth factors, cytokines and integrin-related interactions can activate signaling molecules such as MAPKs, PI3K/ Akt, Wnt/b-catenin, Ras, integrin-linked kinase and focal adhesion kinase. These molecules are capable of inducing epithelialmesenchymal transition. 4 The activation of specific signaling pathways that are mediated by these signaling molecules results in the activation of transcriptional factors, such as Snail and Slug, which repress the expression of E-cadherin. 5 Ovarian cancer is the fifth leading cause of cancer-related deaths among women in developed countries. Ovarian cancer cells with low levels of E-cadherin expression are more invasive, 6 and the absence of E-cadherin expression predicts poor patient survival compared with ovarian tumor cells that express E-cadherin. 7 Epidermal growth factor (EGF)/EGF receptor (EGFR) signaling has an important role in tumor metastasis. 8 Overexpression of EGFR is found in many types of cancer, including ovarian cancer and is associated with more aggressive clinical behavior, and a poor prognosis for survival. [9] [10] [11] Recently, we and other groups have shown that EGF induces ovarian cancer cell invasion by downregulating E-cadherin expression. [12] [13] [14] However, the underlying mechanisms that regulate the EGF-induced downregulation of E-cadherin expression are not fully understood.
Egr-1 was first identified in quiescent fibroblasts as an early response gene that is induced by serum. 15 Egr-1 is rapidly activated by many extracellular signaling molecules, which include growth factors, cytokines, hormones and environmental stresses. 16 Activated Egr-1 regulates the expression of its target genes mainly through the binding to GC-rich, cis-acting elements in the promoter region. 17 Egr-1 has been implicated in the regulation of a number of genes involved in cell growth, apoptosis, differentiation and inflammation. 18 Egr-1 also has an important role in the regulation of tumor angiogenesis and tumor growth. 19 EGF induces Egr-1 expression in both normal and cancer cells. [20] [21] [22] A recent study showed that hepatocyte growth factor (HGF) induces the MAPK signaling-mediated expression of Egr-1, leading to increased Snail expression, which represses E-cadherin in human hepatocellular carcinoma cells. 23 Recently, we showed that EGF downregulates E-cadherin expression and induces cell invasion through the production of H 2 O 2 , the activation of p38 MAPK and the upregulation of Snail in human ovarian cancer cells.
14 However, in human ovarian cancer cells, whether EGF induces the expression of Egr-1 to mediate the EGF-induced downregulation of E-cadherin and increased cell invasion has not been determined. In the current study, our results provide the first evidence that EGF treatment induces Egr-1 expression in human ovarian cancer cells. We also demonstrate that EGF-induced Egr-1 binds the promoter of Slug and promotes its expression, which subsequently mediates the downregulation of E-cadherin and leads to increased cell invasion.
RESULTS

EGF treatment induces Egr-1 expression
To test our hypothesis that EGF treatment induces Egr-1 expression, we first tested the effect of EGF on Egr-1 expression in SKOV3 and OVCAR5 cells. Cells were serum starved for 24 h and then treated with EGF (100 ng/ml) at different time points. As shown in Figure 1a , the basal levels of Egr-1 in SKOV3 and OVCAR5 cells were low. Treatment with EGF induced the Egr-1 protein levels in a time-dependent manner, with the maximal effect observed 1 h after the EGF treatment. Interestingly, the induced Egr-1 protein levels declined after 18 h of EGF treatment (Supplementary Figure 1) . The phosphorylation of EGFR in both cell lines confirmed the activation of EGFR by EGF treatment (Figure 1b) . To further confirm the involvement of EGFR in EGF-induced Egr-1 expression, EGFR-specific small interfering RNA (siRNA) was used to knock down levels of endogenous EGFR. Western blot analysis showed that the EGFR siRNA significantly knocked down endogenous EGFR expression and abolished the EGF-induced Egr-1 expression in SKOV3 and OVCAR5 cells (Figure 1c ). These results indicate that EGF induces Egr-1 expression and that EGFR is required for this function.
ERK1/2 and Akt, but not H 2 O 2 and p38 MAPK, are involved in EGF-induced Egr-1 expression The MAPKs and PI3K/Akt signaling pathways are involved in epithelial-mesenchymal transition in ovarian cancer cells. 24 However, only a few studies have addressed the molecular mechanisms of the EGF-induced downregulation of E-cadherin, and to date, these mechanisms have not been fully elucidated. 24 To examine the molecular signaling involved in EGF-induced Egr-1 expression, cells were treated with inhibitors against MEK1, p38 MAPK and PI3K. To avoid the non-specific effects of pharmacological inhibition, 50 mM PD98059, 10 mM SB203580 or 1 mM Wortmannin was used. 25, 26 Western blot analysis showed that treatment with PD98059 or Wortmannin, but not SB203580, attenuated the EGF-induced Egr-1 expression (Figure 2a) . These results sparked our interest in examining the signaling network underlying the EGF-induced Egr-1 expression. We recently showed that EGF downregulates E-cadherin expression through the production of H 2 O 2 and the activation of p38 MAPK in SKOV3 cells.
14 In OVCAR5 cells, using the H 2 O 2 -specific fluorescent dye CM-H2DCFDA, we also showed that EGF treatment induced H 2 O 2 production in a time-dependent manner (Supplementary Figure 2a) . In addition, EGF-stimulated H 2 O 2 production was eliminated by treatment with the EGFR inhibitor AG1478 and with cell-permeable polyethylene glycol (PEG)-catalase, which is a specific H 2 O 2 scavenger (Supplementary Figure 2b) . To examine whether H 2 O 2 production is involved in EGF-induced Egr-1 expression, cells were treated with PEG-catalase to eliminate the production of H 2 O 2 . As shown in Figure 2b , EGF treatment induced Egr-1 expression; however, PEG-catalase did not affect the level of EGF-induced Egr-1 expression. Taken together, these results indicate that the ERK1/2 and Akt signaling pathways but Figure 1 . EGF induces Egr-1 expression in SKOV3 and OVCAR5 ovarian cancer cells. (a) Cells were treated with 100 ng/ml of EGF, and the expression levels of Egr-1 were examined by western blot. (b) Cells were treated with 100 ng/ml of EGF, and the phosphorylation levels of EGFR at tyrosine 1173 were examined by western blot. (c) Cells were transfected with 50 nM control siRNA (si-Ctrl) or EGFR siRNA (si-EGFR) for 48 hours and were treated with 100 ng/ml EGF for 1 hour. Figure 3) . In addition, the mRNA and protein levels of E-cadherin were downregulated by EGF treatment in OVCAR5 cells (Supplementary Figure 4 ). Reverse transcription quantitative real-time PCR (RT-qPCR) results showed that treatment with PD98059 or Wortmannin attenuated the EGF-induced Snail and Slug mRNA levels, whereas SB203580 attenuated EGF-induced Snail mRNA levels, but did not affect Slug mRNA levels ( Figure 3a) . The results Egr-1 expression is required for EGF-induced Slug, but not Snail To investigate whether Egr-1 mediates EGF-induced Snail and Slug expression, Egr-1-specific siRNA was used to knock down the expression of Egr-1. The results of western blot analysis showed that Egr-1 siRNA treatment significantly knocked down the basal level of Egr-1 expression and EGF-induced Egr-1 expression (Figure 4a ). Interestingly, Egr-1 siRNA treatment diminished EGF-induced Slug mRNA levels, whereas EGF-induced increases in Snail mRNA levels were not affected ( Figure 4b ). Similarly, treatment with Egr-1 siRNA attenuated EGF-induced increases in Slug, but not Snail, protein levels ( Figure 4c ).
The Slug gene is a target of Egr-1 We next investigated the potential role of Egr-1 in the regulation of EGF-mediated Slug expression. To confirm the presence of Egr-1 in the nucleus, cells were treated with EGF, and the expression of Egr-1 in nuclear extracts was examined. The levels of Egr-1 in the non-nuclear fraction were low, and EGF treatmentinduced Egr-1 protein levels were mainly localized in the nuclear fraction ( Figure 5a ). Immunofluorescence staining confirmed the nuclear expression of Egr-1 after EGF treatment. In addition, the EGF-induced nuclear expression of Egr-1 was abolished by Egr-1 siRNA treatment (Figure 5b ). Using TFBIND software (RIKEN Yokohama Institute, Yokohama, Japan), 27 two putative Egr-1 binding sites between À 300 and À 1 upstream of the human Slug gene transcriptional start site were identified (Figure 5c ). We next sought to determine whether Egr-1 could directly bind to the Slug promoter with a chromatin immunoprecipitation (ChIP) assay with anti-Egr-1 antibodies followed by PCR with primers specific for the Slug promoter. ChIP analysis showed that in both SKOV3 and OVCAR5 cells Egr-1 specifically bound to the Slug promoter after 1 h of EGF treatment, while only weak binding occurred in the absence of EGF. The ChIP signal for the binding of Egr-1 to the Slug promoter was abolished by treating cells with Egr-1 siRNA. Normal rabbit immunoglobulin G (IgG) was used as a negative control for the ChIP assay (Figure 5d ).
It has been reported that Egr-1 mediates HGF-induced Snail expression by directly binding to the promoter in HepG2 cells. 23 Our western blot results showed that treatment with HGF induced the Egr-1 protein levels in a time-dependent manner in HepG2 cells and the induction of Egr-1 by HGF was abolished by treating cells with Egr-1 siRNA (Supplementary Figures 5a and b) . Furthermore, RTqPCR results showed that HGF treatment increased Snail mRNA levels in a time-dependent manner and the HGF-induced Snail mRNA levels were attenuated in the cells treated with Egr-1 siRNA (Supplementary Figures 5c and d) . ChIP analysis showed that Egr-1 bound to the Snail promoter after 1 h of HGF treatment (Supplementary Figure 5e) . These results confirmed with the previous study that Snail is a target gene of Egr-1 under HGF treatment in HepG2 cells. 23 To further confirm that Egr-1 is not involved in EGFinduced Snail expression in SKOV3 and OVCAR5 cells, the direct binding of Egr-1 on the Snail promoter was examined. ChIP analysis showed that in both SKOV3 and OVCAR5 cells Egr-1 did not bound to the Snail promoter after 1 h of EGF treatment (Figure 5e ). Taken together, these results demonstrated that Egr-1 mediates EGFinduced Slug, but not Snail, expression in SKOV3 and OVCAR5 cells. (a) Cells were treated with 100 ng/ml of EGF and subjected to cellular fractionation followed by western blot analysis of Egr-1. Levels of a-tubulin and lamin B were used as markers for cytosolic and nuclear fractions, respectively. Non-NE indicates non-nuclear extracts. NE indicates nuclear extract. (b) Cells were transfected with 50 nM control siRNA (si-Ctrl) or Egr-1 siRNA (si-Egr-1) for 48 h and were treated with 100 ng/ml of EGF for 1 h. Nuclear staining (blue) and expression levels of Egr-1 (red) were examined by immunofluorescence staining. Scale bar represents 50 mm. (Figure 6b ). To investigate whether Egr-1 expression is involved in EGF-induced cell invasion, we performed an invasion assay using Boyden chambers coated with Matrigel (BD Biosciences, Mississauga, ON, Canada) Consistent with our previous studies, EGF treatment induced a significant increase in SKOV3 and OVCAR5 cell invasion. Interestingly, EGF-induced cell invasion was attenuated in cells treated with Egr-1 siRNA (Figure 7) . These results indicate that Egr-1 is a mediator that is involved in the EGF-induced downregulation of E-cadherin and in increased ovarian cancer cell invasion. DISCUSSION EGF has been shown to induce Egr-1 expression and to downregulate E-cadherin expression in human cancer cells, contributing to tumorigenesis and metastasis. 20, 28 However, whether Egr-1 mediates the actions of EGF on E-cadherin expression and cell invasion remains unknown. The current study investigated the regulatory relationships between EGF, Egr-1 and E-cadherin in ovarian cancer cells. We report that EGF induces Egr-1 expression through the ERK1/2 and Akt signaling pathways, which are independent of the H 2 O 2 /p38 MAPK signaling pathway. Egr-1 mediates EGF-induced downregulation of E-cadherin expression and is involved in EGF-induced cell invasion. Moreover, our results indicate that Egr-1 binds directly to the Slug promoter and increases Slug expression, which subsequently contributes to the EGF-induced downregulation of E-cadherin expression and increased cell invasion. Our results show that the induction of Egr-1 by EGF is transient, with the maximal effect observed 1 h after treatment and diminished at 24 h. The western blot results showed that treatment with EGF for 3-12 h significantly increased Slug protein levels. In addition, the protein levels of E-cadherin decreased after 24 h of EGF treatment. Taken together, these results indicate that the early induction of Egr-1 by EGF treatment acts to induce the expression of Slug. Subsequently, the increased Slug expression functions as a transcriptional repressor, which contributes to the EGF-induced downregulation of E-cadherin. Our results demonstrate the progression of this pathway, whereby induction of Egr-1 induces Slug upregulation, which in turn downregulates E-cadherin.
Egr-1 is involved in the development of human tumors. 19 However, Egr-1 may act as either a tumor promoter or suppressor, depending on the type of tumor. In prostate cancer cells, Egr-1 can increase tumor progression by regulating both cell survival and cell death. 29 Egr-1 expression also enhances cell invasion by increasing the expression of the human protease-activated receptor-1. 30 Moreover, the tumorigenesis of prostate cancer is significantly impaired in Egr-1-deficient mice. 31 In contrast, the expression level of Egr-1 is decreased in human breast cancer cells, and its loss correlates with the development of the disease. 32 In fibrosarcoma, Egr-1 suppresses cell growth by activating transforming growth factor beta-1. 33 In the current study, we showed that EGF treatment in SKOV3 and OVCAR5 ovarian cancer cells increased expression of Egr-1. In addition, inhibition of Egr-1 by siRNA attenuated the effects of EGF-induced Slug expression and E-cadherin downregulation, and increased cell invasion. Our results suggest that Egr-1 acts as a tumor promoter in the ovarian cancer and that the cooperation of Egr-1 and Slug is associated with the EGF-induced downregulation of E-cadherin and increased cell invasion.
Various extracellular signals can induce the transcriptional activation of Egr-1. 18 The ERK1/2, p38 MAPK and PI3K/Akt signaling pathways have been shown to be involved in the regulation of Egr-1. [34] [35] [36] Previous studies have shown that the activation of ERK1/2 and PI3K/Akt is required for EGF-induced Egr-1 expression. 35, 37 Using pharmacological inhibitors, we showed that ERK1/2 and PI3K/Akt signaling pathways are both partially involved in EGF-induced Egr-1 expression. However, the p38 MAPK inhibitor, SB203580, did not affect levels of EGFinduced Egr-1 expression. In alveolar carcinoma cells, ERK1/2 but not p38 MAPK or PI3K/Akt is involved in EGFR signaling, which mediates Egr-1 activation during hyperoxia. 38 These results indicate that the signaling components that mediate EGFinduced Egr-1 expression may depend on the cellular context.
The transcriptional repression of E-cadherin mainly contributes to the downregulation of E-cadherin. 5 Many transcription factors have been identified that can repress the transcription of E-cadherin. 3 Snail and Slug are two such transcription factors that have been extensively studied. 39, 40 In this study, we show that the ERK1/2 and PI3K/Akt signaling pathways are involved in EGFinduced Snail and Slug expression. However, the p38 MAPK signaling pathway is required for EGF-induced expression of Snail but not of Slug. These results confirm our previous study that EGFinduced H 2 O 2 /p38 MAPK signaling is involved in EGF-induced Snail expression but not EGF-induced Slug expression. 14 In the current study, our results indicate that the induction of Egr-1 by EGF treatment does not require H 2 O 2 production and p38 MAPK activation. Egr-1 siRNA attenuates only EGF-induced Slug expression but not Snail expression. Moreover, ChIP analysis shows for the first time that Egr-1 can bind to the Slug promoter and induce its expression. Taken together, these results indicate that Slug is required for the Egr-1-mediated EGF-induced downregulation of E-cadherin.
A recent study in human hepatocellular carcinoma cells showed that Egr-1 mediates HGF-induced Snail expression by directly binding to the Snail promoter, which contributes to HGF-induced cell scattering. 23 However, HGF treatment does not induce the expression of Slug. 23 In the present study, our ChIP analysis results show that EGF-induced Egr-1 directly binds to the Slug promoter, but not Snial, in SKOV3 and OVCAR5 cells. Analysis of the human Snail promoter showed that the binding of NF-kB and Sp1 transcription factors is involved in the regulation of Snail transcription. 41 Egr-1 and Sp1 have similar consensus sequences for the promoter binding site; therefore, they compete with each other to bind the promoter. 42, 43 Further investigation is required to determine whether the lack of inhibition of EGF-induced Snail expression by Egr-1 siRNA treatment is caused by the involvement of other transcription factors that are involved in the regulation of Snail transcription.
Taken together with the conclusions of our previous study, 14 we provide important insights into the molecular mechanisms mediating the EGF-induced downregulation of E-cadherin and increased cell invasion in ovarian cancer (Figure 8 ). We propose that EGF treatment results in the activation of EGFR and induces H 2 O 2 production and p38 MAPK activation to increase the expression of Snail, an E-cadherin transcription repressor, which subsequently results in the downregulation of E-cadherin. Additionally, EGF engagement of the EGFR activates ERK1/2 and PI3K/Akt signaling pathways, which subsequently induce the expression of Egr-1. The activated Egr-1 increases the expression of Slug, another E-cadherin transcription repressor, to downregulate E-cadherin, which contributes to EGF-induced cell invasion. Figure 8 . Schematic illustrating the pathways for EGF-induced downregulation of E-cadherin and increased cell invasion in human ovarian cancer cells. EGF treatment results in the activation of EGFR to induce H 2 O 2 production and p38 MAPK activation, which increase the expression of Snail, an E-cadherin transcription repressor, leading to the downregulation of E-cadherin. After binding to EGFR, EGF also activates the ERK1/2 and PI3K/Akt signaling pathways, which induce the expression of Egr-1. The activated Egr-1 increases the expression of Slug, another E-cadherin transcription repressor, to downregulate E-cadherin, which contributes to EGF-induced cell invasion.
MATERIALS AND METHODS
Cell culture
The human ovarian cancer cell line SKOV3 was obtained from American Type Culture Collection (Manassas, VA, USA). OVCAR5 ovarian cancer line was kindly provided by Dr T.C. Hamilton (Fox Chase Cancer Center, Philadelphia, PA, USA). Cells were grown in a 1:1 (v/v) mixture of M199/ MCDB105 medium (Sigma-Aldrich, Oakville, ON, USA) supplemented with 10% fetal bovine serum (Hyclone Laboratories Inc., Logan, UT, USA). HepG2 cell line was kindly provided by Dr Geoffrey Hammond at University of British Columbia. HepG2 cells were grown in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum. Cultures were maintained at 37 1C in a humidified atmosphere of 5% CO 2 in air.
Antibodies and reagents 
Western blot analysis
Cells were lysed in cell lysis buffer (Cell Signaling). Equal amounts of protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinyl difluoride (PVDF) membranes. Following blocking for 1 h with 5% non-fat dry milk in Tris-buffered saline, membranes were incubated overnight at 4 1C with primary antibodies, which were diluted in 3% bovine serum albumin/Tris-buffered saline. Following the primary antibody incubation, membranes were incubated with the appropriate horseradish peroxidase-conjugated secondary antibody. Immunoreactive bands were detected with an enhanced chemiluminescent substrate. Membranes were stripped with stripping buffer at 50 1C for 30 min and reprobed with anti-b-actin as a loading control.
Reverse transcription quantitative real-time PCR Total RNA was extracted using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. Reverse transcription was performed with 3 mg RNA, random primers and M-MLV reverse transcriptase (Promega, Madison, WI, USA). The primers used for SYBR Green reverse transcription-qPCR (RTqPCR) were as follows: E-cadherin, 5 0 -ACAGCCCCGCCTTATGATT-3 0 (sense) and 5 0 -TCGGAACCGCTTCCTTCA-3 0 (antisense); Snail, 5 0 -CCCCAATCGGAAG CCTAACT-3 0 (sense) and 5 0 -GCTGGAAGGTAAACTCTGGATTAG A-3 0 (antisense); Slug, 5 0 -TTCGGACCCACACATTACCT-3 0 (sense) and 5 0 -GCAGTGA GGGCAAGAAAAAG-3 0 (antisense); and GAPDH, 5 0 -GAGTCAACGGATTTGG TCGT-3 0 (sense) and 5 0 -GACAAGCTTCCCGTTCTCAG-3 0 (antisense). RT-qPCR was performed using the Applied Biosystems 7300 Real-Time PCR System (Applied Biosystems Inc, Foster City, CA, USA) equipped with a 96-well optical reaction plate. All RT-qPCR experiments were run in triplicate, and a mean value was used for the determination of mRNA levels. Relative quantification of the mRNA levels was performed using the comparative Ct method with GAPDH as the reference gene and with the formula 2 -DDCt .
Nuclear-cytoplasmic fractionation Nuclear-cytoplasmic fractionation was conducted using the NE-PER Nuclear and Cytoplasmic Extraction Reagents kit (Pierce, Rockford, IL, USA) according to the manufacturer's protocol.
Immunofluorescence staining Cells were cultured on coverslips and fixed in 4% paraformaldehyde for 15 min. After washing, cells were permeabilized in 0.1% Triton/PBS solution for 5 min. The coverslips were blocked with Dako Protein Block (Dako, Mississauga, ON, USA) for 1 h and incubated with an antibody to Egr-1 diluted in Dako Protein Block. Alexa 594-labeled donkey anti-rabbit IgG was used as a secondary antibody. Cells were counterstained with Hoechst 33258 (Sigma), rinsed with PBS, mounted with Gelvatol, and examined using a Zeiss Axiophot epifluorescence microscope equipped with a digital camera (Q Imaging, Burnaby, BC, Canada).
Chromatin immunoprecipitation
The ChIP assay was performed with the use of the ChIP-IT kit (Active Motif, Carlsbad, CA, USA) according to the manufacturer's protocol. Briefly, cells were fixed in 1% formaldehyde at room temperature for 10 min; the fixation reaction was stopped by adding glycine stop-fix solution to the dish at room temperature for 5 min. After washing, the cells were resuspended in lysis buffer and incubated for 30 min on ice. The cells were homogenized and nuclei were resuspended in shearing buffer and subjected to pre-optimized ultrasonic disruption conditions to yield 200-1500 bp DNA fragments. Sheared chromatin (25 mg) was incubated in ChIP buffer with protein G magnetic beads and Egr-1 antibody or rabbit IgG (Cell Signaling) as a negative control on a rolling shaker overnight at 4 1C. The immunoprecipitated chromatin was purified from the chromatinantibody mixture with several washing steps, and the chromatinimmunoprecipitated DNA was eluted in elution buffer. Crosslinking was reversed by adding reverse-crosslink buffer. 0 . 23 The selected primers were confirmed with an in silico PCR program (http://genome.cse.ucsc.edu/cgi-bin/hgPcr) to ensure the generation of a single amplicon from the human genomic DNA. The PCR products (Slug: 347 bp and Snail: 219 bp) were resolved by electrophoresis in a 1% agarose gel and visualized by ethidium bromide staining.
Invasion assay
Invasion assays were performed in Boyden chambers according to a previously published method, with minor modifications. 44 Transwell filters (8 mm pore size, 24 wells, BD Biosciences) were coated with 1 mg/ml of growth factor-reduced Matrigel. Cells in M199/MCDB105 medium that was supplemented with 0.1% fetal bovine serum were incubated for 24 h against a gradient of 10% fetal bovine serum. Cells that penetrated the membrane were fixed with cold methanol, and the cell nuclei were stained with Hoechst 33258 and counted by epifluorescence microscopy using Northern Eclipse 6.0 software (Empix Imaging, Mississauga, ON, USA). Triplicate inserts were used for each individual experiment, and five microscopic fields were counted per insert.
Statistical analysis
Results are presented as the mean±s.e.m. of at least three independent experiments and were analyzed using the one-way analysis of variance test followed by Tukey's test using PRISM software (GraphPad Software Inc, La Jolla, CA, USA). A significant difference was defined as Po0.05.
